Name | MSA-2 |
---|---|
Synonyms | 5,6-dimethoxy-γ-oxo-benzo[b]thiophene-2-Butanoic Acid |
Description | MSA-2 is an orally available non-nucleotide STING agonist, with EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models[1]. |
---|---|
Related Catalog | |
In Vivo | MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals[1]. MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor[1]. Animal Model: MC38 tumor-bearing C57BL6 mice[1] Dosage: 60 mg/kg Administration: P.o. ; s.c (50 mg/kg); single dose Result: PO or SC doses of MSA-2 that effectively inhibited tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor. |
References |
Molecular Formula | C14H14O5S |
---|---|
Molecular Weight | 294.32 |
Storage condition | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |